Commit Biologics

The company's core technology is the Bispecific Complement Engaging (BiCE™) platform. This platform uses single-domain antibodies that bind to the C1q protein, which initiates the classical complement pathway, a powerful but previously underexploited part of the innate immune system. The BiCE™ technology is designed as a modular system that can be combined with established antibodies to direct the complement system in a highly targeted manner, selectively killing tumor cells or cells implicated in autoimmune diseases. This approach is intended to overcome the limitations of conventional monoclonal antibodies, which are often poor activators of the complement system. By supercharging these antibodies, Commit Biologics aims to develop best-in-class therapeutics while potentially reducing development timelines and risks.

Commit Biologics has secured significant funding to advance its platform. The company exited stealth mode in May 2024 with €16 million in seed funding from Novo Holdings and Bioqube Ventures. This was followed by a €5.5 million extension in January 2025 from new investor Korys, bringing the total seed financing to €21.5 million. This funding provides a financial runway into late 2026 and will be used to advance the BiCE™ platform toward drug candidate selection. The company's board includes representatives from its key investors, such as Eva Van Overmeire from Korys. In June 2025, Commit established a Scientific Advisory Board composed of industry experts to guide the development of its technology.